Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase Ib Study of Copanlisib in Combination With Nivolumab or With Nivolumab and Ipilimumab

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03502733
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:57.753131+00:00
Published At
2026-04-13T00:00:00+00:00
Record Updated At
2026-04-13
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Lymphoma", "Metastatic Malignant Solid Neoplasm", "Recurrent Malignant Solid Neoplasm", "Unresectable Malignant Solid Neoplasm"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-13"
protocolSection.identificationModule.nctId
"NCT03502733"
protocolSection.identificationModule.officialTitle
"Phase Ib Study of Copanlisib in Combination With Nivolumab or With Nivolumab and Ipilimumab"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Lymphoma (protocolSection.conditionsModule.conditions)
  • Metastatic Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Recurrent Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Unresectable Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.